Precision BioSciences presents new preclinical data on Pbgene-DMD program

Precision BioSciences (DTIL) announced new preclinical data from its Pbgene-DMD program in an oral presentation at the American Society of Gene & Cell Therapy, ASGCT, 2026 Annual Meeting in Boston, Massachusetts. The new data show that treatment with Pbgene-DMD in early-juvenile mice resulted in significantly higher efficacy across key skeletal and respiratory muscles than treatment in late-juvenile mice over a comparable timeframe. This new data further supports evaluating Pbgene-DMD in younger DMD patient populations, including the 2- to 3-year-old patients, who are a key demographic of the ongoing Phase 1/2 Function-DMD trial evaluating Pbgene-DMD in boys ages 2 to 7. Key data: New preclinical data show Pbgene-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice; Findings further support evaluation of Pbgene-DMD in DMD patient populations as young as 2 years of age; Greater efficacy with earlier intervention further differentiates Pbgene-DMD from microdystrophin approaches